S. Rebouissou

发表

Mutation of TP53 gene is involved in carcinogenesis of hepatic undifferentiated (embryonal) sarcoma of the adult, in contrast with Wnt or telomerase pathways: an immunohistochemical study of three cases with genomic relation in two cases.

B. Bloch, J. Zucman‐Rossi, S. Lepreux, 2005, Journal of hepatology.

Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.

J. Zucman‐Rossi, D. Calvisi, Xin Chen, 2019, Cell metabolism.

Loss of hepatocyte nuclear factor 1α function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis

Sandrine Imbeaud, Alain Paris, Laura Pelletier, 2010, Hepatology.

A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis.

É. Remy, F. Radvanyi, L. Calzone, 2015, Cancer research.

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

Xavier Paoletti, François Radvanyi, Fabien Reyal, 2014, Science Translational Medicine.

Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.

P. Gestraud, E. Barillot, N. López-Bigas, 2014, Cell reports.

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

Jessica Zucman-Rossi, Michael R Stratton, Sandrine Imbeaud, 2015, Nature Genetics.

Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas

S. Imbeaud, J. Zucman‐Rossi, V. Paradis, 2020, Gut.

MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations

Laura Pelletier, J. Zucman‐Rossi, S. Rebouissou, 2008, Hepatology.

Sigma 1 Receptor Is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α

J. Zucman‐Rossi, M. Pontoglio, E. Chevet, 2020, Cancers.

Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry

Cristel G. Thomas, S. Imbeaud, J. Zucman‐Rossi, 2007, Hepatology.

Genotype phenotype classification of hepatocellular adenoma.

J. Zucman‐Rossi, S. Rebouissou, C. Balabaud, 2007, World journal of gastroenterology.

Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.

J. Zucman‐Rossi, H. Blanché, P. Laurent-Puig, 2004, Journal of hepatology.

Hepatocellular carcinoma hosts immature neurons and cholinergic tumors that correlate with adverse molecular features and outcomes

F. Zoulim, A. Viari, S. Rebouissou, 2022, bioRxiv.

Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy

M. Loriot, P. Beaune, D. Hémon, 2005, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

NRF2/KEAP1 and Wnt/β‐catenin in the multistep process of liver carcinogenesis in humans and rats

S. Rebouissou, J. Nault, Jessica Zucman Rossi, 2015, Hepatology.

Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas.

Cristel G. Thomas, J. Zucman‐Rossi, P. Laurent-Puig, 2005, Human molecular genetics.

Hepatocellular carcinoma hosts immature neurons and cholinergic tumors that correlate with adverse molecular features and outcomes

F. Zoulim, A. Viari, S. Rebouissou, 2022, bioRxiv.

Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro

M. Ziol, S. Imbeaud, J. Zucman‐Rossi, 2017, Clinical Cancer Research.

Nosology and Molecular Classification of Hepatocellular Adenomas

S. Imbeaud, J. Zucman‐Rossi, V. Paradis, 2016 .

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

S. Boyault, J. Zucman‐Rossi, D. Rickman, 2007, Hepatology.

APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures

S. Imbeaud, J. Zucman‐Rossi, E. Letouzé, 2019, Oncoimmunology.

Mutation of TCF1 encoding hepatocyte nuclear factor 1α in gynecological cancer

J. Zucman‐Rossi, P. Laurent-Puig, X. Sastre, 2004, Oncogene.

Note of caution: Contaminations of hepatocellular cell lines.

Richard Moreau, Jessica Zucman-Rossi, J. Zucman‐Rossi, 2017, Journal of hepatology.

Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression

S. Imbeaud, J. Zucman‐Rossi, E. Letouzé, 2016, Hepatology.

Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC

J. Zucman‐Rossi, V. Paradis, P. Laurent-Puig, 2006, Hepatology.

Advances in molecular classification and precision oncology in hepatocellular carcinoma.

S. Rebouissou, J. Nault, 2020, Journal of hepatology.

The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules.

C. Auffray, S. Imbeaud, J. Zucman‐Rossi, 2008, Journal of hepatology.

Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.

M. Ziol, J. Zucman‐Rossi, V. Paradis, 2020, Journal of hepatology.

Germline hepatocyte nuclear factor 1α and 1β mutations in renal cell carcinomas

Cristel G. Thomas, J. Zucman‐Rossi, P. Laurent-Puig, 2005 .

PI3K/AKT pathway activation in bladder carcinogenesis

Y. Allory, F. Radvanyi, J. Calderaro, 2014, International journal of cancer.

The role of telomeres and telomerase in cirrhosis and liver cancer

J. Zucman‐Rossi, S. Rebouissou, J. Nault, 2019, Nature Reviews Gastroenterology & Hepatology.

Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.

J. Zucman‐Rossi, J. Calderaro, L. Terracciano, 2013, Journal of hepatology.

HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines

J. Zucman‐Rossi, S. Rebouissou, P. Bioulac-Sage, 2011, BMC Cancer.

Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer.

J. Zucman‐Rossi, E. Letouzé, S. Rebouissou, 2021, Cancer discovery.

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3‐mutated urothelial bladder carcinoma

E. Letouzé, Y. Allory, F. Radvanyi, 2012, The Journal of pathology.

A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.

S. Imbeaud, J. Zucman‐Rossi, P. Laurent-Puig, 2013, Gastroenterology.

Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver.

J. Zucman‐Rossi, H. Blanché, P. Laurent-Puig, 2005, Gastroenterology.

Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma.

J. Zucman‐Rossi, S. Rebouissou, P. Bioulac-Sage, 2008, Journal of hepatology.

Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours

S. Imbeaud, J. Zucman‐Rossi, S. Rebouissou, 2009, Nature.

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.

S. Imbeaud, J. Zucman‐Rossi, E. Letouzé, 2019, Gastroenterology.

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

S. Imbeaud, J. Zucman‐Rossi, V. Paradis, 2017, Gastroenterology.

Dual Targeting of Histone Methyltransferase G9a and DNA‐Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

R. Urtasun, F. Prósper, J. Zucman‐Rossi, 2019, Hepatology.

Mutation of TCF1 encoding hepatocyte nuclear factor 1alpha in gynecological cancer.

J. Zucman‐Rossi, P. Laurent-Puig, X. Sastre, 2004, Oncogene.

Recurrent activating mutations of PPARγ associated with luminal bladder tumors

Y. Allory, F. Radvanyi, H. Lang, 2019, Nature Communications.

Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas

J. Zucman‐Rossi, V. Paradis, E. Letouzé, 2018, Hepatology.

Identification of targeted therapy for an aggressive subgroup of muscle-invasive bladder cancers

Y. Allory, F. Radvanyi, I. Bernard-Pierrot, 2015, Molecular & cellular oncology.

A phosphokinome‐based screen uncovers new drug synergies for cancer driven by liver‐specific gain of nononcogenic receptor tyrosine kinases

J. Zucman‐Rossi, J. Calderaro, Fabrice Daian, 2017, Hepatology.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

M. Ziol, C. Copie-Bergman, S. Imbeaud, 2020, Hepatology.

HNF1α Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation*

C. Auffray, S. Imbeaud, J. Zucman‐Rossi, 2007, Journal of Biological Chemistry.

Recurrent activating mutations of PPAR gamma associated with luminal bladder tumors.

Y. Allory, F. Radvanyi, H. Lang, 2019 .

Reply to « Glutamine synthetase staining and CTNNB1 mutation in hepatocellular adenomas »

J. Zucman‐Rossi, J. Calderaro, S. Rebouissou, 2017 .

CLINICAL — LIVER A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection

S. Imbeaud, A. Reyniès, J. Llovet, 2013 .

The role of telomeres and telomerase in cirrhosis and liver cancer

J. Zucman‐Rossi, S. Rebouissou, J. Nault, 2019, Nature Reviews Gastroenterology & Hepatology.

Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression

S. Imbeaud, J. Zucman‐Rossi, E. Letouzé, 2016, Hepatology.

Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.

P. Gestraud, E. Barillot, N. López-Bigas, 2014, Cell reports.

RSK2 inactivation cooperates with AXIN1 inactivation or ß-catenin activation to promote hepatocarcinogenesis.

J. Zucman‐Rossi, J. Calderaro, S. Rebouissou, 2023, Journal of hepatology.

Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival.

S. Imbeaud, G. Nagae, S. Rebouissou, 2024, European journal of cancer.

Note of caution: Contaminations of hepatocellular cell lines.

J. Zucman‐Rossi, R. Moreau, S. Rebouissou, 2017, Journal of hepatology.